Tumor Evasion and New Targets

Tumors have a great capacity for adaptation and are able to set in motion multiple resistance mechanisms in response to treatment. 

Our work focuses on understanding these mechanisms by which tumors are able to resist and evade the effects of treatments such as radiotherapy or immunotherapy in order to identify new therapies and combinations that improve survival and quality of life of patients.

To carry out our research we have a multidisciplinary team, as well as sophisticated animal models and cutting-edge technologies for the identification of new therapeutic targets for pancreatic cancer. In the laboratory we use functional genomics to identify genes that mediate resistance to treatment by performing in vivo genetic screening experiments in preclinical models of pancreatic cancer. By applying technologies such as single cell transcriptomic analysis (scRNA seq) we can also study changes in the tumor microenvironment that allow us to understand the mechanisms of action of the antitumor response in different contexts. All this is supported by a close collaboration with other renowned groups, both national and international, in research centers such as the Broad Institute (Cambridge, US) or the Weizmann Institute (Israel).

Not least, the group's philosophy is based on scientific quality in an environment of solidarity, teamwork and constant learning.

This group is integrated in the Cancer Center Clínica Universidad de Navarra.